William Blair Issues Optimistic Forecast for Exagen Earnings

Exagen Inc. (NASDAQ:XGN) – Analysts at William Blair lifted their Q1 2025 earnings per share (EPS) estimates for Exagen in a research report issued to clients and investors on Wednesday, March 12th. William Blair analyst A. Brackmann now forecasts that the company will post earnings of ($0.20) per share for the quarter, up from their previous forecast of ($0.24). William Blair has a “Outperform” rating on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share. William Blair also issued estimates for Exagen’s Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.55) EPS.

XGN has been the topic of a number of other research reports. Canaccord Genuity Group boosted their price target on Exagen from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Cantor Fitzgerald restated an “overweight” rating and set a $8.00 price target on shares of Exagen in a research note on Monday, January 13th.

Exagen Price Performance

Shares of NASDAQ XGN opened at $3.56 on Friday. Exagen has a fifty-two week low of $1.30 and a fifty-two week high of $6.22. The company has a market cap of $62.79 million, a PE ratio of -3.79 and a beta of 1.40. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.05 and a current ratio of 4.05. The business has a 50-day simple moving average of $3.78 and a two-hundred day simple moving average of $3.57.

Institutional Investors Weigh In On Exagen

A number of large investors have recently bought and sold shares of XGN. Verus Capital Partners LLC purchased a new stake in Exagen in the third quarter valued at approximately $39,000. Stonepine Capital Management LLC boosted its position in Exagen by 49.0% in the third quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock valued at $1,651,000 after buying an additional 175,701 shares during the last quarter. Palumbo Wealth Management LLC boosted its position in Exagen by 13.5% in the fourth quarter. Palumbo Wealth Management LLC now owns 86,704 shares of the company’s stock valued at $355,000 after buying an additional 10,340 shares during the last quarter. Corient Private Wealth LLC purchased a new stake in Exagen in the fourth quarter valued at approximately $45,000. Finally, Virtu Financial LLC purchased a new stake in Exagen in the fourth quarter valued at approximately $46,000. Hedge funds and other institutional investors own 75.25% of the company’s stock.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).